{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:nivatrotamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01152788: Phase 2 Interventional Completed Melanoma
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tirnovetmab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04594642: Phase 1 Interventional Recruiting B-cell Non Hodgkin Lymphoma
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03485118: Phase 2 Interventional Completed Diffuse Large B-cell Lymphoma
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tezatabep matraxetan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02921945: Phase 3 Interventional Unknown status Hemophilia A
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:sigvotatug vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
